P
Description
Biotech company founded in 2019 in Oxford/Cambridge, UK, developing therapeutics for Huntington's disease symptoms including involuntary choreatic movements, psychiatric/behavioural disturbances, and neurodegenerative dementia. Founded by Martin Quibell, Timothy Schulz-Utermoehl and Fraser Murray. Raised $1.43M across 2 rounds. Acquired in December 2022.